SBIR/STTR Research Award

STTR Phase I: Fungal Expression of Antimicrobial Peptides for Addition to Animal Feed

Award identifier b1d891656606ce10b9a0fa2f210b7c30e321edf01d649fba420d905b50e1f024Awarding agency National Science Foundation

Award amount

$225,000

Program and phase

STTR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
Mycoinnovation
Proposal award date
2013-07-01
Contract end date
2014-06-30
UEI
Not reported
Solicitation number
Not reported
Topic code
EB

Research abstract

This Small Business Technology Transfer (STTR) Phase I project will develop antimicrobial peptides (AMP) as an alternative to antibiotics that are used as growth promotants in animal feed. It is common practice to add low doses of medically important antibiotics to animal feed to improve production efficiency. However, this practice has been shown to lead to antibiotic-resistant bacterial strains, which have the potential to infect humans. As an alternative to traditional antibiotics, the goal is to test the potential of antimicrobial peptides. Because antimicrobial peptides are not used for human therapy, concerns regarding bacterial resistance are significantly diminished. The key limitation in using AMP has been the inability to produce them at cost effective levels. To overcome this challenge, the first step of this project will be to express a number of different AMP in filamentous fungal fermentations, which have the potential to produce tremendous amounts of recombinant protein at greatly reduced cost. If successful, this proof-of-concept study will justify additional research to determine the efficacy of AMP in livestock. The broader impact/commercial potential of this project, if successful, is the reduction of antibiotic use in animal feeds. Some estimates place the worldwide market for animal-feed antibiotics at over $4 billion annually. However, to reduce bacterial antibiotic resistance, the FDA has recently published new guidance restricting traditional antibiotics to therapeutic use. Numerous alternatives to medically important antibiotics have been proposed, but the application of antimicrobial peptides shows great promise. The most significant limitation to their commercial application has been cost of production. Thus, the ability to economically manufacture these peptides would represent a significant benefit to the agricultural industry as it would allow farmers to maintain high levels of productivity while not generating antibiotic-resistant strains that pose a danger to humans.

Technology keywords

Not reported

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.